A synergistic effect of a combined bivalent DNA-protein anti-HIV-1 vaccine containing multiple T- and B-cell epitopes of HIV-1 proteins

Molecular Immunology

Volumn 45, Issue 3, 2008, Pages 661-669

  Bazhan, Sergei I ^a   Karpenko, Larisa I ^a   Lebedev, Leonid R ^a   Uzhachenko, Roman V ^a   Belavin, Pavel A ^a   Eroshkin, Alexey M ^a   Ilyichev, Alexander A ^a  

^a STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

Author keywords

Combined polyepitope DNA protein vaccine; HIV 1; Immunogenicyty; Synergistic effect; T and B cell epitopes; Virus like particle

Indexed keywords

CD4 ANTIGEN; DEOXYRIBONUCLEOPROTEIN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS 1 PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS 1 VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN; TBI PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGEN PRESENTATION; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HIV-1; MICE; MICE, INBRED BALB C; VACCINES, DNA; VIRAL PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34848813798     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.07.016     Document Type: Article

References (42)

1. Ahlers J.D., Belyakov I.M., Thomas E.K., and Berzofsky J.A. High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J. Clin. Invest. 108 (2001) 1677-1685
2. Bazhan S.I., Belavin P.A., Seregin S.V., Danilyuk N.K., Babkina I.N., Karpenko L.I., Nekrasova N.A., Lebedev L.R., Ignatyev G.M., Agafonov A.P., Poryvaeva V.A., Aborneva I.V., and Ilyichev A.A. Designing and engineering of DNA-vaccine construction encoding multiple CTL epitopes of major HIV-1 antigens. Vaccine 22 (2004) 1672-1682
3. Belyakov I.M., Hel Z., Kelsall B., Kuznetsov V.A., Ahlers J.D., Nacsa J., Watkins D.I., Allen T.M., Sette A., Altman J., Woodward R., Markham P.D., Clements J.D., Franchini G., Strober W., and Berzofsky J.A. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7 (2001) 1320-1326
4. Berzofsky J.A., Pendleton C.D., Clerici M., Ahlers J., Lucey D.R., Putney S.D., and Shearer G.M. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J. Clin. Invest. 88 (1991) 876-884
5. Brave A., Ljungberg K., Boberg A., Rollman E., Engstrom G., Hinkula J., and Wahren B. Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine 24 (2006) 4524-4526
6. Clemens J., Brenner R., and Rao M. Interactions between PRP-T vaccine against Haemophilus influenzae type b and conventional infant vaccines. Lessons for future studies of simultaneous immunization and combined vaccines. Ann. N.Y. Acad. Sci. 31 (1995) 255-266
7. Clerici M., Piconi S., Balotta C., Trabattoni D., Capetti A., Fusi M.L., Ruzzante S., Longhi R., Colombo M.C., Moroni M., and Milazzo F. Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. J. Infect. Dis. 175 (1997) 1210-1215
8. Clerici M., Tacket C.O., Via C.S., Lucey D.R., Muluk S.C., Zajac R.A., Boswell R.N., Berzofsky J.A., and Shearer G.M. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur. J. Immunol. 21 (1991) 1345-1349
9. Eroshkin A.M., Karginova E.A., Gileva I.P., Lomakin A.S., Lebedev L.R., Kamyinina T.P., Pereboev A.V., and Ignat'ev G.M. Design of four-helical protein as a candidate for HIV vaccine. Protein Eng. 8 (1995) 167-173
10. Firat H., Tourdot S., Ureta-Vidal A., Scardino A., Suhrbier A., Buseyne F., Riviere Y., Danos O., Michel M.L., Kosmatopoulos K., and Lemonnier F.A. Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice. Eur. J. Immunol. 10 (2001) 3064-3074
11. Gonzalo R.M., Rodríguez D., García-Sastre A., Rodríguez J.R., Palese P., and Esteban M. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine 17 (1999) 887-892
12. Guarnieri F.G., Arterburn L.M., Penno M.B., Cha Y., and August J.T. The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1. J. Biol. Chem. 25 (1993) 1941-1946
13. Hanke T., Schneider J., Gilbert S.C., Hill A.V., and McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 16 (1998) 426-435
14. Hosmalin A., Nara P.L., Zweig M., Lerche M.W., Cease K.B., Gard E.A., Markham P.D., Putney S.D., Daniel M.D., and Desrosiers R.C. Priming with T-helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in Primates. J. Immunol. 146 (1991) 1667-1673
15. Insel R.A. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann. N. Y. Acad. Sci. 31 (1995) 35-47
16. Karpenko L.I., Bazhan S.I., Ignat'ev G.M., Lebedev L.R., Il'ichev A.A., and Sandakhchiev L.S. Artificial anti-HIV immunogens and methods of their delivery. Vestn. Ross. Akad. Med. Nauk 1 (2003) 24-30
17. Karpenko L.I., Ilyichev A.A., Eroshkin A.M., Lebedev L.R., Uzhachenko R.V., Nekrasova N.A., Plyasunova O.A., Belavin P.A., Seregin S.V., Danilyuk N.K., Zaitsev B.N., Danilenko E.D., Masycheva V.I., and Bazhan S.I. Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine. Design, immunogenicity and toxicity studies. Vaccine 25 (2007) 4312-4323
18. Karpenko L.I., Lebedev L.R., Ignatyev G.M., Agafonov A.P., Poryvaeva V.A., Pronyaeva T.R., Ryabchikova E.I., Pokrovsky A.G., and Ilyichev A.A. Construction of artificial virus-like particles exposing HIV epitopes, and the study of their immunogenic properties. Vaccine 21 (2003) 386-392
19. Karpenko L.I., Nekrasova N.A., Ilyichev A.A., Lebedev L.R., Ignatyev G.M., Agafonov A.P., Zaitsev B.N., Belavin P.A., Seregin S.V., Danilyuk N.K., Babkina I.N., and Bazhan S.I. Comparative analysis using a mouse model of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CTL-immunogen. Vaccine 22 (2004) 1692-1699
20. Konishi E., Terazawa A., and Imoto J. Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice. Vaccine 21 (2003) 1826-1832
21. Lebedev L.R., Karpenko L.I., Poryvaeva V.A., Azaev M.Sh., Riabchikova E.I., Gileva I.P., and Il'ichev A.A. Design of virus-like particles, exposing HIV-1 epitopes. Mol. Biol. (Mosk) 34 (2000) 480-485
22. Lofthouse S. Immunological aspects of controlled antigen delivery. Adv. Drug Deliv. Rev. 54 (2002) 863-870
23. Loktev V.B., Ilyichev A.A., Eroshkin A.M., Karpenko L.I., Pokrovsky A.G., Pereboev A.V., Svyatchenko V.A., Ignat'ev G.M., Smolina M.I., Melamed N.V., Lebedeva C.D., and Sandakhchiev L.S. Design of immunogens as components of a new generation of molecular vaccines. J. Biotechnol. 44 (1996) 129-137
24. Lorin C., Delebecque F., Labrousse V., Da Silva L., Lemonnier F., Brahic M., and Tangy F. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 23 (2005) 4463-4472
25. Lowry O.H., Rosenbrough N.J., Farr A.L., and Randall J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
26. McIntyre P.B., Turnbull F.M., Egan A.M., Burgess M.A., Wolter J.M., and Schuerman L.M. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine 23 (2004) 380-385
27. Men Y., Audran R., Thomasin C., Eberl G., Demotz S., Merkle H.P., Gander B., and Corradin G. MHC class I- and class II restricted processing and presentation of microencapsulated antigens. Vaccine 17 (1999) 1047-1056
28. Muthumani K., Bagarazzi M., Conway D., Hwang D.S., Ayyavoo V., Zhang D., Manson K., Kim J., Boyer J., and Weiner D.B. Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques. J. Med. Primatol. 31 (2002) 179-185
29. Nawrath M., Pavlovic J., and Moelling K. Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model. J. Mol. Med. 79 (2001) 133-142
30. O'Hagan D.T. Recent advances in vaccine adjuvants for systemic and mucosal administration. J. Pharm. Pharmacol. 50 (1998) 1-10
31. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Pankratz V.S., and Poland G.A. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: Findings and implications for vaccine design. Vaccine 25 (2007) 3090-3100
32. Paradiso P.R. Combination vaccines for diphtheria, tetanus, pertussis, and Haemophilus influenzae type b. Ann. N. Y. Acad. Sci. 31 (1995) 108-113
33. Peyre M., Audran R., Estevez F., Corradin G., Gander B., Sesardic D., and Johansen P. Childhood and malaria vaccines combined in biodegradable microspheres produce immunity with synergistic interactions. J. Control. Release 99 (2004) 345-355
34. Ramshaw I.A., and Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21 (2000) 163-165
35. Rowell J.F., Ruff A.L., Guarnieri F.G., Staveley-O'Carroll K., Lin X., Tang J., August J.T., and Siliciano R.F. Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. J. Immunol. 155 (1995) 1818-1828
36. Ruff A.L., Guarnieri F.G., Staveley-O'Carroll K., Siliciano R.F., and August J.T. The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. J. Biol. Chem. 272 (1997) 8671-8678
37. Shirai M., Kurokohchi K., Pendleton C.D., Arichi T., Boyd L.F., Takahashi H., Margulies D.H., and Berzofsky J.A. Reciprocal cytotoxic T lymphocytes cross-reactivity interactions between two major epitopes within HIV-1 gp160. J. Immunol. 157 (1996) 4399-4411
38. Shirai M., Pendleton C.D., and Berzofsky J.A. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. J. Immunol. 148 (1992) 1657-1667
39. Spiro R.G. Analysis of sugars found in glycoproteins. Methods Enzymol. 7 (1966) 3-25
40. Thomasin C., Corradin G., Men Y., Merkle H.P., and Gander B. Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J. Control. Release 41 (1996) 131-148
41. Vesikari T., Baer M., and Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr. Infect. Dis. J. 26 (2007) 153-158
42. Woodberry T., Gardner J., Mateo L., Eisen D., Medveczky J., Ramshaw I.A., Thomson S.A., Ffrench R.A., Elliott S.L., Firat H., Lemonnier F.A., and Suhrbier A. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes. J. Virol. 73 (1999) 5320-5325